Visceral fat area and cardiometabolic risk: The Kardiovize study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F21%3A00075097" target="_blank" >RIV/00159816:_____/21:00075097 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14310/21:00121420

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/abs/pii/S1871403X21000478?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/abs/pii/S1871403X21000478?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.orcp.2021.03.005" target="_blank" >10.1016/j.orcp.2021.03.005</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Visceral fat area and cardiometabolic risk: The Kardiovize study

Popis výsledku v původním jazyce

Background: Visceral fat is associated with adiposity-based complications. Bioimpedance measurement allows estimation of visceral fat area (VFA) in an easy manner. However, a validated cut-off value for VFA by bioimpedance associated with cardiometabolic risk is lacking in European population. Aim: To determine cut-off values of VFA measured via bioimpedance associated with cardiometabolic risk. Methods: Random cross-sectional Czech population-based sample of 25-64 years old subjects. Receiver Operating Characteristic (ROC) curves were used and the area under the curve (AUC), sensitivity, and specificity were calculated. The Cardiometabolic Disease Staging System (CMDS) was used to classify cardiometabolic risk: Stage 1 - 1 or 2 metabolic syndrome (MetS) components, without impaired fasting glucose (IFG); Stage 2 - MetS or IFG; Stage 3 - MetS with IFG; Stage 4 - type 2 diabetes and/or cardiovascular disease. Results: 2052 participants (54.5% females, median age 49 years) were included. Median VFA (inter-quartile range) were 82.2 cm(2) (54.8) in men and 89.8 cm(2) (55.6) in women. The best VFA cut-offs associated with Stage 1 in men and women were 71 cm(2)(sensitivity = 0.654; specificity = 0.427) and 83 cm(2) (sensitivity = 0.705; specificity = 0.556); Stage 2: 84 cm(2) (sensitivity = 0.673; specificity = 0.551) and 98 cm(2) (sensitivity = 0.702; specificity = 0.628); Stage 3: 90 cm(2) (sensitivity = 0.886; specificity = 0.605) and 109 cm(2) (sensitivity = 0.755; specificity = 0.704); Stage 4: 91 cm(2)(sensitivity = 0.625; specificity = 0.611) and 81cm(2) (sensitivity = 0.695; specificity = 0.448), respectively. Conclusion: A cut-off value of VFA of 71 cm(2) in men and 83 cm(2) in women exhibited the earliest stage of cardiometabolic risk, and 90 cm(2) in men and 109 cm(2) in women showed the best performance to detect risk. (C) 2021 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.

Název v anglickém jazyce

Visceral fat area and cardiometabolic risk: The Kardiovize study

Popis výsledku anglicky

Background: Visceral fat is associated with adiposity-based complications. Bioimpedance measurement allows estimation of visceral fat area (VFA) in an easy manner. However, a validated cut-off value for VFA by bioimpedance associated with cardiometabolic risk is lacking in European population. Aim: To determine cut-off values of VFA measured via bioimpedance associated with cardiometabolic risk. Methods: Random cross-sectional Czech population-based sample of 25-64 years old subjects. Receiver Operating Characteristic (ROC) curves were used and the area under the curve (AUC), sensitivity, and specificity were calculated. The Cardiometabolic Disease Staging System (CMDS) was used to classify cardiometabolic risk: Stage 1 - 1 or 2 metabolic syndrome (MetS) components, without impaired fasting glucose (IFG); Stage 2 - MetS or IFG; Stage 3 - MetS with IFG; Stage 4 - type 2 diabetes and/or cardiovascular disease. Results: 2052 participants (54.5% females, median age 49 years) were included. Median VFA (inter-quartile range) were 82.2 cm(2) (54.8) in men and 89.8 cm(2) (55.6) in women. The best VFA cut-offs associated with Stage 1 in men and women were 71 cm(2)(sensitivity = 0.654; specificity = 0.427) and 83 cm(2) (sensitivity = 0.705; specificity = 0.556); Stage 2: 84 cm(2) (sensitivity = 0.673; specificity = 0.551) and 98 cm(2) (sensitivity = 0.702; specificity = 0.628); Stage 3: 90 cm(2) (sensitivity = 0.886; specificity = 0.605) and 109 cm(2) (sensitivity = 0.755; specificity = 0.704); Stage 4: 91 cm(2)(sensitivity = 0.625; specificity = 0.611) and 81cm(2) (sensitivity = 0.695; specificity = 0.448), respectively. Conclusion: A cut-off value of VFA of 71 cm(2) in men and 83 cm(2) in women exhibited the earliest stage of cardiometabolic risk, and 90 cm(2) in men and 109 cm(2) in women showed the best performance to detect risk. (C) 2021 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Obesity Research &amp; Clinical Practice

ISSN

1871-403X

e-ISSN

—

Svazek periodika

15

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

368-374

Kód UT WoS článku

000675529000010

EID výsledku v databázi Scopus

—